“…For example, the combination of adhesion and angiotensin II stimulation has been shown to result in the phosphorylation of paxillin LIM2 T396/401 and LIM3 S455/479, which is believed to target paxillin to sites of focal adhesions [99]. Although LIM2 has been shown to associate and co-immunoprecipitate with a kinase that can phosphorylate threonines 396/401 in human cells and LIM3 to bind a detergent-insoluble kinase that can phosphorylate serines 455/479, when tested, these kinases were immune to inhibition by a variety of broad-spectrum serine/threonine kinase inhibitors, suggesting that the identity of these kinases are novel in nature [66,86,120]. Despite this however, several candidate serine/threonine kinases have been identified for paxillin including: protein kinase C, MAPK, JNK, ERK1/2, the p21-activated protein kinase PAK3 and the integrin-linked kinase, ILK [121,122].…”